Literature DB >> 9681472

Constitutive activity and structural instability of the wild-type human H2 receptor.

A E Alewijnse1, M J Smit, M Hoffmann, D Verzijl, H Timmerman, R Leurs.   

Abstract

Stable expression of the human H2 receptor in Chinese hamster ovary cells resulted in an increase in basal cyclic AMP (cAMP) production, which was inhibited by the inverse agonists cimetidine, famotidine, and ranitidine with potencies similar to those found for the rat H2 receptor. Burimamide, a neutral antagonist at the rat H2 receptor, behaved as a weak partial agonist at the human H2 receptor. Burimamide competitively antagonized both the histamine-induced increase in cAMP and the cimetidine-induced reduction of the basal cAMP level with apparent K(B) values that were similar to its H2 receptor affinity. Investigation of the modulation of receptor expression after long-term drug treatment revealed that at low concentrations histamine induced a significant reduction in H2 receptor expression, whereas at high concentrations receptor expression was slightly increased. The partial agonist burimamide induced, like inverse agonists, an up-regulation of the human H2 receptor after prolonged treatment. These findings suggest a structural instability of the constitutively active human H2 receptor in transfected Chinese hamster ovary cells. Occupation of the H2 receptor by any ligand reduces the instability, thus resulting in higher cellular expression levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681472     DOI: 10.1046/j.1471-4159.1998.71020799.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

1.  Modulation of histamine H(2) receptor signalling by G-protein-coupled receptor kinase 2 and 3.

Authors:  M S Rodriguez-Pena; H Timmerman; R Leurs
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Mechanisms of inverse agonist action at D2 dopamine receptors.

Authors:  David J Roberts; Philip G Strange
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

4.  Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors.

Authors:  A Rouleau; X Ligneau; J Tardivel-Lacombe; S Morisset; F Gbahou; J-C Schwartz; J-M Arrang
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo.

Authors:  Marie Humbert-Claude; Elisabeth Davenas; Florence Gbahou; Ludwig Vincent; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2011-09-13       Impact factor: 4.530

Review 6.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 7.  The Roles of Cardiovascular H2-Histamine Receptors Under Normal and Pathophysiological Conditions.

Authors:  Joachim Neumann; Uwe Kirchhefer; Stefan Dhein; Britt Hofmann; Ulrich Gergs
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

8.  Chemical Probes for Histamine Receptor Subtypes.

Authors:  Markus Falkenstein; Milica Elek; Holger Stark
Journal:  Curr Top Behav Neurosci       Date:  2022

9.  Pharmacological characterization of human incretin receptor missense variants.

Authors:  Jean-Philippe Fortin; Jonathan C Schroeder; Yuantee Zhu; Martin Beinborn; Alan S Kopin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

10.  Functional selectivity of adenosine receptor ligands.

Authors:  Dennis Verzijl; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2011-05-05       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.